Pharmaceutical News

RSS

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Queen's receives NICH&S grant to create vaccine against Pseudomonas

Queen's University Belfast scientists working on a vaccine to combat Pseudomonas have received a financial boost from Northern Ireland Chest Heart and Stroke.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

NMR techniques shed new light on how pharma molecules adopt different polymorphic forms

Scientists at the University of Warwick have used state-of-the-art nuclear magnetic resonance (NMR) techniques to shed new light on how pharmaceutical molecules pack together in the solid state.

8 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

Researchers make significant strides in the study of Intrahepatic Cholangiocarcinoma

Researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center have made significant strides in the study of a primary cancer of the liver- Intrahepatic Cholangiocarcinoma (IHCC), also called biliary tract cancer.

8 Mar 2012

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the treatment of schizophrenia.

8 Mar 2012

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.

7 Mar 2012

AMTR soon after failure of AEDs may reduce risk of seizures in epilepsy patients

Patients with epilepsy who underwent brain surgery soon after failing to respond to drug treatment, but who also continued to receive drug therapy, had a lower risk of seizures during the 2nd year of follow-up compared to patients who received drug treatment alone, according to a study in the March 7 issue of JAMA.

7 Mar 2012

New FDA approved drug to treat infants with respiratory distress syndrome

Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

7 Mar 2012

Majority of Missourians continue to favor nonprescription access to PSE-containing medicines

The Consumer Healthcare Products Association (CHPA) released today a recent poll that found a majority of Missourians -- by a margin of 16 percent -- continue to favor nonprescription access to safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex-D, and Sudafed over a prescription mandate.

7 Mar 2012

Ivabradine could save thousands of heart failure patients

Researchers behind a major trial of Procoralan believe the pill could save 10,000 lives a year in Britain alone. Ivabradine works by slowing the beating of the heart, helping it to pump blood more efficiently.

7 Mar 2012

VBC files patent applications related to beneficial health effects of S-ABA

Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.

7 Mar 2012

Are Americans overdosing on cholesterol lowering statins?

Eric Topol, Chief Academic Officer for Scripps Health and cardiologist, wrote an ‘op-ed’ in the New York Times Opinion Page addressing the risk of cholesterol-reducing statins such as Lipitor, Zocor and Crestor.

7 Mar 2012

Many Ethiopians coming to camp in search of traditional cure for HIV turn to ARVs, WSJ reports

The Wall Street Journal examines how many HIV-positive Ethiopians coming to a "squatter's camp" at Ethiopia's Entoto Mountain in the hopes that a spring believed to contain holy water would cure HIV instead begin treatment with antiretrovirals.

7 Mar 2012

Pten gene can also fight against obesity, ageing process

This result, obtained after five years' research, is published in leading journal Cell Metabolism. The authors, led by Manuel Serrano (CNIO), believe it will open the door to new therapeutic options not only against cancer, but against obesity and even the ageing process.

7 Mar 2012

Researchers reveal how melanoma develops resistance to Zelboraf

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

7 Mar 2012

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

FDA approves Discovery Labs' SURFAXIN to prevent Respiratory Distress Syndrome

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.

6 Mar 2012